Efficacy of prolonged azithromycin versus switching to doxycycline in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children
MA Yi-Chen, ZHOU Xi-Hui, ZHAO Xiao-Dan, WANG Chen-Yang
Department of Pediatrics, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China
Abstract：Objective To investigate the efficacy and safety of prolonged azithromycin (PAZM) versus switching to doxycycline (SDXC) in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia (MUMPP) in children. Methods A total of 173 children with MUMPP who were hospitalized in Baoji Central Hospital, from January to December 2023 were selected as subjects. According to the choice of secondary antibiotic after 72 hours of initial macrolide therapy, they were divided into two groups: PAZM and SDXC. The efficacy and adverse drug reactions were compared between the two groups, and the risk factors for refractory Mycoplasma pneumoniae pneumonia (RMPP) were analyzed. Results Compared with the PAZM group, the SDXC group had significantly shorter time to defervescence and time to cough relief, a significantly lower proportion of patients using glucocorticoids, and a significantly higher proportion of patients with lung lesion absorption (P<0.05). No adverse reactions such as liver and kidney function impairment and tooth discoloration were observed in either group. RMPP occurred in 47 cases in the PAZM group. The univariate analysis showed that lactate dehydrogenase levels and age were risk factors for RMPP (P<0.05). Conclusions The efficacy of SDXC is superior to that of PAZM in children with MUMPP, and short-term use of doxycycline is relatively safe.
MA Yi-Chen,ZHOU Xi-Hui,ZHAO Xiao-Dan et al. Efficacy of prolonged azithromycin versus switching to doxycycline in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children[J]. CJCP, 2024, 26(12): 1294-1300.
Hubert D, Dumke R, Weichert S, et al. Emergence of macrolide-resistant Mycoplasma pneumoniae during an outbreak in a primary school: clinical characterization of hospitalized children[J]. Pathogens, 2021, 10(3): 328. PMID: 33802078. PMCID: PMC7999249. DOI: 10.3390/pathogens10030328.
Shah SS, Test M, Sheffler-Collins S, et al. Macrolide therapy and outcomes in a multicenter cohort of children hospitalized with Mycoplasma pneumoniae pneumonia[J]. J Hosp Med, 2012, 7(4): 311-317. PMID: 22271440. DOI: 10.1002/jhm.1904.
Ishiguro N, Koseki N, Kaiho M, et al. Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients[J]. PLoS One, 2017, 12(3): e0173635. PMID: 28288170. PMCID: PMC5348022. DOI: 10.1371/journal.pone.0173635.
Chen J, Qi X, Yin Y, et al. Effects of minocycline on macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children: a single-center retrospective study[J]. Transl Pediatr, 2021, 10(11): 2997-3004. PMID: 34976765. PMCID: PMC8649588. DOI: 10.21037/tp-21-356.
Kawai Y, Miyashita N, Kubo M, et al. Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients[J]. Antimicrob Agents Chemother, 2013, 57(5): 2252-2258. PMID: 23459497. PMCID: PMC3632908. DOI: 10.1128/AAC.00048-13.
Xie Q, Zhang X, Cui W, et al. Construction of a nomogram for identifying refractory Mycoplasma pneumoniae pneumonia among macrolide-unresponsive mycoplasma pneumoniae pneumonia in children[J]. J Inflamm Res, 2022, 15: 6495-6504. PMID: 36474517. PMCID: PMC9719700. DOI: 10.2147/JIR.S387809.
